Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
July 07, 2015 12:00 AM

Hospitals slam GAO finding that 340B drug discounts fuel prescribing

Virgil Dickson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Pixabay

    Hospitals say the U.S. Government Accountability Office used faulty methodology when it determined that hospitals that serve large numbers of low-income patients abuse a federal drug discount by overprescribing medications.

    HHS raised similar concerns about the findings.

    Hospitals that serve a disproportionate number of low-income patients have access to discounted outpatient drug prices through the 340B Drug Pricing Program, which is administered by HHS.

    The GAO report released Monday found that in both 2008 and 2012, per-beneficiary Medicare Part B drug spending, including oncology drug spending, was substantially higher at hospitals utilizing the 340B discount than at other hospitals.

    “This indicates that, on average, beneficiaries at 340B disproportionate share hospitals (DSH) were either prescribed more drugs or more expensive drugs than beneficiaries at the other hospitals in GAO's analysis,” the watchdog agency said.

    For example, in 2012, average per-beneficiary spending at 340B DSH hospitals was $144, compared to approximately $60 at non-340B hospitals.

    Provider trade groups questioned how the GAO came up with its results. They said the report doesn't take into account that 340B hospitals may see sicker patients than other hospitals, and noted that the GAO may have unfairly ignored other reasons for higher spending, including the fact that patients of non-340B hospitals more frequently receive drugs in non-hospital settings.

    “None of this stopped GAO from reaching unsupported conclusions and policy recommendations based on its faulty analysis,” Dr. Bruce Siegel, CEO of America's Essential Hospitals, a trade group for safety net hospitals, said in a statement. “We're surprised not only by the lack of evidence and data for GAO's conclusions and recommendations, but also by its suggestion that physicians in our nation's essential hospitals would ignore patient needs to enrich hospitals.”

    American Hospital Association Senior Vice President Tom Nickels made similar criticisms of the methodology in a newsletter to members. "Simply put, the GAO report misses the mark,” he said.

    340B Health, an association of more than 1,000 hospitals, echoed those remarks in its own statement, and appears to have an ally in HHS, which expressed similar skepticism in its response to the report.

    “We are concerned that the report characterizing spending on Part B in 340B DSH hospitals … is not supported by the study methodology,” HHS said. “GAO's study, which only examined average difference in per-beneficiary spending by hospital type, did not examine any patient differences in terms of outcomes or quality.”

    A GAO representative stood by the methodology.

    “We carefully examined several factors that could potentially affect Part B drug spending and, even after accounting for these factors, found substantial differences in spending between 340B DSH and non-340B hospitals," said Chuck Young, managing director of the GAO's office of public affairs.

    He added that several classifications that might result in higher proportions of low-income patients could not explain the substantial differences in Part B drug spending the GAO found.

    “Also, to understand whether the substantially higher payments could be due in part to patients who were more likely to receive Part B drugs in non-hospital settings, we also conducted an analysis that was limited to patients who only received Part B drugs in a hospital outpatient department," Young said.

    The analysis found that higher spending at 340B DSH hospitals persisted, and was more than twice as high at those hospitals than at non-340B DSH hospitals.

    There were 1,039 disproportionate share hospitals participating in the 340B program as of May 31, 2013, the last year a federal count was available, according to congressional data.

    The program has been around since 1992, but was expanded after the Affordable Care Act allowed more providers to become eligible for the discount. The number of participants taking advantage of the discounts has since risen.

    More troubling, is the potential that overprescribing may be how hospitals “maximize Medicare revenues,” the report stated. “While hospitals may be financially benefiting … this poses potentially serious consequences to the Medicare program and its beneficiaries,” the agency said.

    The GAO suggested that Congress consider eliminating the incentive to prescribe more drugs or more expensive drugs than necessary to treat Medicare Part B beneficiaries at 340B hospitals.

    Safety net providers and clinics that participate in the 340B program are expected to meet this month to address the criticisms. They're now contending with a pile of reports that cast a shadow over the program.

    An analysis released last year by Avalere Health and sponsored by the pharmaceutical industry-backed advocacy group, Alliance for Integrity and Reform, found that roughly two-thirds of hospitals participating in the 340B program provide less charity care than the average U.S. hospital, with charity care making up 1% or less of total costs at a quarter of those facilities.

    An analysis conducted by the Berkeley Research Group found that drug purchases made at the 340B price rose from $1.1 billion in 1997 to more than $7 billion in 2013, with projections of reaching more than $16 billion by 2020.

    More positive studies include an analysis conducted in May by healthcare policy consulting firm Dobson DaVanzo & Associates. It found that 340B hospitals provided nearly twice as much care to Medicaid and low-income Medicare beneficiaries as hospitals that did not participate in the program.

    The Health Resources and Services Administration, the federal agency that regulates 340B, estimated that the program saved providers about $3.8 billion in drug costs in 2013.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    congress prescription drugs
    PBMs, Big Pharma face off in House hearing
    Biden COVID copy_i_i.jpg
    Biden administration asks employers to help more workers who lose Medicaid
    Most Popular
    1
    CMS tries luring providers to revamped Medicare ACOs
    2
    Oregon joins other states in setting ratios for nurse staffing
    3
    Blue Shield CA taps Amazon, Mark Cuban, CVS for new PBM model
    4
    A health innovation hub grows in Lake Nona Medical City
    5
    Hospital-at-home providers push for Medicaid coverage
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing